Can Catalyst, Sucampo, and Peregrine keep the momentum going?
News & Analysis: Peregrine Pharmaceuticals
Peregrine Pharmaceuticals' shares rose 15% in November, and two subtle press releases provided the spark.
Peregrine Pharmaceuticals' stock had a rough September. Should investors take advantage of this pullback to add this speculative biopharma to their portfolios?
If you skipped Peregrine Pharmaceuticals' conference call, then you missed management discussing these five important events and strategies.
Little-known Peregrine Pharmaceuticals reports solid revenue growth and pipeline achievements in its first-quarter report -- but is this small-cap cancer immunotherapy developer really investment material?
Interest is starting to heat up in the cancer immunotherapy space, and small-cap biotech Peregrine Pharmaceuticals finds itself squarely at ground zero.
Peregrine Pharmaceuticals produced market-topping results in the fourth quarter, but it's the juicy details from its conference call that stole the show.
Peregrine Pharmaceuticals may have topped Wall Street's expectations in Q4, but we have to dig beneath the headline figures to find the truly important takeaways.
Peregrine Pharmaceuticals is set to report its fourth-quarter and full-year results on Tuesday, July 14. Here are a few factors that investors would be wise to pay attention to when the results are released.
Our experts weigh in.